FDA approves first interchangeable biosimilar
AstraZeneca still eyes US vaccine filing despite another delay
AstraZeneca and Amgen quietly admit tezepelumab defeat as the Dupixent challenger heads to FDA
Eli Lilly hands Kumquat Biosciences $70M to kick off cancer drug R&D alliance
*please scroll down for all the latest news*
